ASTRID OTTEN CARRANZA: Open Payments
NPI 1902345192 · CHICO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$808 in 45 payments from 14 companies in 2025. Trend: 2023 $653 · 2024 $814 · 2025 $808
Food & beverage: $808
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $201 |
| ABBVIE INC. | 13 | $150 |
| Janssen Pharmaceuticals, Inc | 4 | $113 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Dexcom, Inc. | 2 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| ALK-Abello, Inc | 1 | $21 |
Products named: FANAPT, SPRAVATO, QULIPTA, VRAYLAR, Dexcom G6 Transmitter, REXULTI, INGREZZA, HETLIOZ.
Industry payments across CA — which companies pay providers there.
